ConcertAI, a pacesetter in oncology generative and agentic AI SaaS and multi-modal knowledge (MMD) options for healthcare and life sciences, in the present day introduced the combination of the American Society of Medical Oncology (ASCO) Tips via the CARAai platform for its Precision Suite and CancerLinQ SmartLinQ options™. Now, the ability of the Precision Suite’s low-latency and high-recency knowledge can be utilized by biopharma researchers to evaluate Guideline-concordant care and outcomes at any cut-off date or reviewing adjustments over time. Members of the CancerLinQ® community utilizing SmartLinQ options will now have ASCO Guideline-concordant suggestions for his or her particular person sufferers as an augmentation of their evaluation of remedy choices. This revealed data can be built-in with different SmartLinQ options that may assist oncologists take into account a whole set of remedy choices for optimized affected person outcomes.
Additionally Learn: Amperity Unveils Business’s First Id Decision Agent, Accelerating AI Readiness for Enterprise Manufacturers
In December of 2023, ASCO and ConcertAI introduced the acquisition of CancerLinQ and ongoing community operations as a ConcertAI initiative. Over the past 12 months and a half, ConcertAI has superior the SmartLinQ utility for QOPI purposes in addition to superior notifications of probably helpful diagnostics and newly accepted therapeutics for a supplier’s sufferers. SmartLinQ works straight inside the workflows of Epic and different EMRs. ASCO Tips can be augmenting the SmartLinQ resolution by June fifteenth as a part of the corporate’s effort to guarantee that each one community practices have that informational useful resource.
On Might 30th, ConcertAI introduced its oncology Precision Suite™ of generative and agentic AI options for advancing analytics and inferences, and for medical trial design and optimization. The ASCO Tips can be obtainable inside these options by June 30th for evaluation of Guideline-concordant care throughout the widest array of settings, and to tell the design of medical trial controls in accordance with revealed medical suggestions.
Learn: AI in Content material Creation: High 25 AI Instruments
“By CancerLinQ, ConcertAI has an nearly decade-long historical past of collaborating with ASCO,” stated Jeff Elton, Ph.D., Vice Chairman of ConcertAI. “This license of ASCO Tips represents a brand new alternative to harness the most recent generative and agentic AI applied sciences to advertise high-quality most cancers care, proof era, and superior care insights.”
[To share your insights with us, please write to psen@itechseries.com]
